Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0292 in bronchiectasis with chronic Pseudomonas aeruginosa colonization
2025-523009-14-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis and Pseudomonas aeruginosa colonization comparing AZD0292 with Placebo (2 arms). Primary endpoint: Annualized rate of exacerbations. Planned start Dec 2025; status: authorised.
02
Drugs
AZD-0292
03
Conditions
bronchiectasisPseudomonas aeruginosa colonization
Beyond the preview
Go deeper on 2025-523009-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523009-14-00.